Page 10 - Preclinical Data News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Immunicum AB Immunicum AB Presents Preclinical Data for Ilixadencel and DCP-001 at the 18th Cancer Immunotherapy Annual Meeting Immunicum AB Presents Preclinical Data for Ilixadencel and DCP-001 at the 18th Cancer Immunotherapy Annual Meeting Press Release 03 May 2021 Immunicum AB Presents Preclinical Data for Ilixadencel and DCP-001 at the 18th Cancer Immunotherapy Annual Meeting Immunicum AB (publ; IMMU.ST) announced today the publication of two abstracts for oral presentations covering preclinical data on its lead programs, ilixadencel and DCP-001, at the 18 th Cancer Immunotherapy (CIMT)...

Bicycle Therapeutics plc: Bicycle Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update Toxin Conjugates (BTCs) and tumor targeted immune cell agonists (TICAs) Cash of $136.0 million at December 31, 2020 expected to provide financial runway through multiple clinical milestones First clinical trial site outside of the United States opened in ongoing Phase I/II trial of BT8009 Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide ( Bicy...

Precigen Reports Fourth Quarter and Full Year 2020 Financial Results - Company successfully accomplished anticipated 2020 clinical milestones despite challenges due to the ongoing pandemic - - Strengthened balance sheet with successful public offering while streamlining operations and reducing operating costs - - Initial data readouts from PRGN-3005 and PRGN-3006 UltraCAR-T® clinical trials demonstrated encouraging expansion, persistence and clinical activity - - A PRGN-3006 UltraCAR-T patient achieved complete remission with incomplete hematologic recovery (CRi) per ELN criteria - - Initiat...

Celltrion Healthcare Celltrion Group announces positive top-line efficacy and safety data from global Phase II/III clinical trial of COVID-19 treatment candidate CT-P59 Wednesday, January 13, 2021 3:52PM IST (10:22AM GMT)     CT-P59 (40mg/kg) treated patients reported reduced progression rates to severe COVID-19 by 54% for patients with mild-to-moderate symptoms and 68% for moderate patients aged 50 years and over CT-P59 (40mg/kg) treated patients reported a significantly shortened time to clinical recovery ranging from 3.4 to 6.4 days quicker compared to placebo A significant reduction of ...